According to an article by US media outlet Riverbender on January 18th, Senate Majority Whip Dick Durbin met with co-founder of the anti-e-cigarette coalition PAVe, Meredith Berkman, to discuss concerns about the US Food and Drug Administration's (FDA) efforts to protect children from the harms of e-cigarettes.
Debbie expresses dissatisfaction with the FDA's failure to comply with the court's mandated actions, including missing the federal court's deadline of December 31, 2023.
Former Congressman Devin Nunes recently wrote a letter to FDA Commissioner Robert Califf urging him to take action to protect children and put a halt to the illegal sale of e-cigarette products. In his letter, Nunes revealed the FDA's failure to enforce the statutory deadline for regulating synthetic nicotine products.
Devon once again strongly criticizes the FDA, accusing it of failing to clear addictive and enticing e-cigarettes for children, despite manufacturers being long overdue in submitting pre-market tobacco product applications. The final deadline for these applications was September 9, 2021, but the FDA has exceeded the 28-month deadline set by the court, resulting in unauthorized e-cigarettes flooding the market, posing a threat to the health of American children.
During the meeting with Burkeman, Debin emphasized that he will continue to push in the Senate and urge the FDA to take immediate public health protective measures.
He also successfully passed a bipartisan provision in the 2022 fiscal year omnibus spending bill with Senator Susan Collins, which clarifies the FDA's regulatory authority over synthetic nicotine products, helping to prevent e-cigarette manufacturers from circumventing FDA oversight through legal loopholes. The new law requires the FDA to remove all unauthorized synthetic nicotine products from the market by July 13, 2022.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
